Day: June 27, 2025

BOSTON, June 27, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines’ daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer. “Almost all MTAP-del pancreatic and approximately 30% of lung cancers have a co-occurring RAS mutation, and preclinical data show strong combination activity of TNG462 with either daraxonrasib or zoldonrasib. Single agent clinical data to date have demonstrated these molecules to be well-tolerated and active in pancreatic cancer and lung cancer,...

Not for distribution to United States Newswire Services or for dissemination in the United States. VANCOUVER, British Columbia, June 27, 2025 (GLOBE NEWSWIRE) —  Nevada Lithium Resources Inc. (TSXV: NVLH; OTCQB: NVLHF; FSE: 87K) (“Nevada Lithium” or the “Company”) is pleased to announce that it will extend the expiry date of an aggregate of 19,488,992 outstanding common share purchase warrants (the “Warrants”) for a further 24-month period to July 7, 2027. The Warrants were previously set to expire on July 7, 2025, and all other terms of the Warrants remain the same. The proposed amendment remains subject to the approval of the TSX Venture Exchange (the “Exchange”) The Warrants were issued in connection with a private placement of subscription receipts (each a “Subscription Receipt”) completed on February 24, 2023, for aggregate...

Singapore, June 27, 2025 (GLOBE NEWSWIRE) — Webuy Global Ltd. (Nasdaq: WBUY) (“Webuy” or the “Company”), a fast-growing Southeast Asian e-commerce and travel technology company, has entered into a strategic Memorandum of Understanding (MOU) with CTG MICE Service Company Limited.(“CTG MICE”), a subsidiary of China Tourism Group Travel Services Co. Ltd., which is part of China Tourism Group Corporation Limited (“CTG”), the largest state-owned tourism enterprise in China. The partnership aims to jointly develop and scale inbound tourism services to China. Under this landmark partnership, both companies will jointly facilitate the annual arrival of at least 20,000 Chinese inbound travelers by enhancing infrastructure, designing curated travel routes, and delivering premium VIP services. By leveraging AI-powered itinerary planning,...

HOUSTON, June 27, 2025 (GLOBE NEWSWIRE) — NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2025 results on Tuesday, July 29, 2025, at 10 a.m. (Central Time). NOV will issue a press release with the Company’s results after the market closes for trading on Monday, July 28, 2025. The call will be webcast live on www.nov.com/investors.  About NOVNOV delivers technology-driven solutions to empower the global energy industry. For more than 150 years, NOV has pioneered innovations that enable its customers to safely produce abundant energy while minimizing environmental impact. The energy industry depends on NOV’s deep expertise and technology to continually improve oilfield operations and assist in efforts to advance the energy transition towards a more sustainable future. NOV powers the industry that powers...

DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution. “Eton’s addition to the Russell 2000 and Russell 3000 Indexes is a significant milestone and recognizes the tremendous shareholder value we’ve generated over the past twelve months. We’re proud to be part of these important market performance benchmarks and look forward to expanding our visibility among investors as we continue bringing much needed treatments to patients with ultra-rare conditions,”...

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association’s 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland. Details of the presentations are as follows:Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning, M.D.Format: Poster Presentation, #22Date, time:...

SINGAPORE and SHANGHAI, June 27, 2025 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or the “Company”), a key player in the global hotel industry, today announced that the 2025 annual general meeting of the Company (the “AGM”) was held on June 27, 2025. During the AGM, the following proposed resolutions were duly passed:the ordinary resolution as set out in the notice of the AGM dated May 8, 2025 (the “Notice of AGM”) regarding the ratification of appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as auditor of the Company for 2025 and the authorization for the directors of the Company to determine the remuneration of the auditor; the ordinary resolution as set out in the Notice of AGM regarding re-election of Ms. Jie Zheng (appointed by the board of directors of the Company...

June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market. This purchase order is to service US hospitals through BioPorto’s distribution relationship with Roche Diagnostics. Currently, ProNephro AKITM (NGAL) has FDA 510(k) marketing clearance for Roche’s cobas® c501 analyzers, that are broadly available in standard medical laboratories and hospitals. Peter Mørch Eriksen, BioPorto’s Group...